Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risperidone extended release - Lyndra Therapeutics

Next Previous
Drug Profile

Risperidone extended release - Lyndra Therapeutics

Alternative Names: LYN-005

Latest Information Update: 18 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lyndra
  • Class Antidepressants; Antineoplastics; Antipsychotics; Behavioural disorder therapies; Fluorinated hydrocarbons; Isoxazoles; Mood stabilisers; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Schizoaffective disorder; Schizophrenia

Most Recent Events

  • 04 Apr 2025 Lyndra withdraws a phase III Starlyng-2 trial prior to enrolment in Schizophrenia and Schizoaffective disorder (PO) due to the reason that sponsor stopped the operations (NCT06878833)
  • 10 Mar 2025 Lyndra plans a phase III Starlyng-2 trial for Schizophrenia (In adults) in April 2025 (NCT06878833)
  • 23 Jan 2025 Lyndra Therapeutics plans phase III pivotal safety trial of oral weekly risperidone in first half of 2025 (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top